Phathom Pharmaceuticals Inc Forecast, price target & analysts
Phathom Pharmaceuticals Inc Target price 2026 - Analyst rating & recommendation
Phathom Pharmaceuticals Inc Classifications & Recommendation
Phathom Pharmaceuticals Inc Price Target
| Target Price | $22.44 |
| Price | $7.30 |
| Potential |
207.40%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target Phathom Pharmaceuticals Inc 2027 .
The average Phathom Pharmaceuticals Inc target price is $22.44.
This is
207.40%
register free of charge
$30.45
317.12%
register free of charge
$13.13
79.86%
register free of charge
|
|
| A rating was issued by 17 analysts: 15 Analysts recommend Phathom Pharmaceuticals Inc to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Phathom Pharmaceuticals Inc stock has an average upside potential 2027 of
207.40%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 175.11 | 321.83 |
| 216.94% | 83.79% | |
| EBITDA Margin | -91.00% | 3.98% |
| 81.83% | 104.37% | |
| Net Margin | -126.35% | -19.76% |
| 79.12% | 84.36% |
14 Analysts have issued a sales forecast Phathom Pharmaceuticals Inc 2026 . The average Phathom Pharmaceuticals Inc sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Phathom Pharmaceuticals Inc EBITDA forecast 2026. The average Phathom Pharmaceuticals Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
13 Phathom Pharmaceuticals Inc Analysts have issued a net profit forecast 2026. The average Phathom Pharmaceuticals Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.03 | -0.79 |
| 42.72% | 73.93% | |
| P/E | negative | |
| EV/Sales | 2.98 |
13 Analysts have issued a Phathom Pharmaceuticals Inc forecast for earnings per share. The average Phathom Pharmaceuticals Inc EPS is
This results in the following potential growth metrics and future valuations:
Phathom Pharmaceuticals Inc...
Current Phathom Pharmaceuticals Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Leerink Partners |
Locked
➜
Locked
|
Locked | Sep 09 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Aug 17 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jul 31 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Jul 31 2026 |
| Needham |
Locked
➜
Locked
|
Locked | Jul 30 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 17 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Mar 27 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Sep 09 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Aug 17 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jul 31 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Jul 31 2026 |
|
Locked
Needham:
Locked
➜
Locked
|
Jul 30 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 17 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Mar 27 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
